---
layout: post
title: "Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Guidance for Industry; Availability"
date: 2026-02-05 18:53:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-01789
original_published: 2024-01-30 00:00:00 +0000
significance: 8.00
---

# Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Guidance for Industry; Availability

**Published:** February 05, 2026 18:53 UTC
**Source:** Federal Register
**Original Published:** January 30, 2024 00:00 UTC
**Document Number:** 2024-01789

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Guidance for Industry." The guidance is intended to assist sponsors, including industry and academic sponsors, developing ex vivo- manufactured CAR T cell products. The guidance provides CAR T cell specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and design of clinical studies for oncology indications (including hematologic malignancies and solid tumors). The guidance announced in this notice finalizes the draft guidance of the same title dated March 2022.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/01/30/2024-01789/considerations-for-the-development-of-chimeric-antigen-receptor-t-cell-products-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2024-01789

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
